Sponsors

Metrion Biosciences invests in expanded facilities

Metrion Biosciences Limited has recently launched its high-throughput screening (HTS) capability, coinciding with the expansion of its state-of-the-art laboratory and office facilities.

Scott Maidment has been appointed as Head of HTS to lead the new service.

The company has signed a nine-year lease for an additional 8,160 square foot of space adjacent to its headquarters on Granta Park, Cambridge, UK, giving a combined total of 20,000 square foot. The new facility and HTS capabilities, which include 384 well screening via FLIPR Penta and Qube-384, will provide significant additional capacity and flexibility to serve ongoing and future ion channel drug discovery projects for Metrion’s global client base. The company has also installed an Agilent Bravo liquid handling robot, adding further capacity to its suite of automated sample preparation and compound handling instruments.

Scott Maidment has been appointed as Head of HTS to lead the introduction of the new service. Scott joins Metrion from Charles River Laboratories, where he was Senior Research Leader. He has almost 30 years’ experience of bioscience laboratory work, including over 20 years in drug discovery contract research for global clients. Scott has extensive expertise in ion channel research gained through multiple HTS campaigns, screening support services, and integrated medicinal chemistry projects targeting transient receptor potential (TRP), two pore domain, calcium-activated K+, ligand- and voltage-gated channel families.

“Following significant growth in Metrion’s global business in 2022, particularly within the USA, the newly acquired space will ensure our ambitious plan for global commercial expansion continues to gather momentum,” said Dr Andrew Southan, Chief Executive of Metrion Biosciences. “The launch of our HTS capability adds another layer of depth to our ion channel drug discovery services and complements our automated and conventional electrophysiology services. Having personally worked with Scott on multiple drug discovery projects prior to joining the Metrion team, I have total confidence in his abilities as a HTS specialist to deliver first class screening services to our clients.”

For more information: https://metrionbiosciences.com.

 

Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

The British Association for Cytopathology Annual Scientific Meeting

Aztec Hotel and Spa, Bristol, BS32 4TS
18 October, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024